Fox Chase Cancer Center News

PHILADELPHIA (July 27, 2020)—In a recent review article, Fox Chase Cancer Center researchers outlined obstacles, research methods, and future treatment prospects for patients with Von Hippel-Lindau (VHL) disease.

PHILADELPHIA (July 22, 2020)—Researchers at Fox Chase Cancer Center have developed a new method for growing and storing medulloblastoma tumor cells, a step that could assist researchers in the development of new drugs. Stromal cells called astrocytes facilitate the signaling pathway that is associated with the formation of medulloblastoma, the most common type of malignant brain tumor found in children.

PHILADELPHIA (July 17, 2020) – Scientists at Fox Chase Cancer Center and Ben-Gurion University of the Negev (BGU) have received a new grant from the United States-Israel Binational Science Foundation (BSF) that will fund continuing research on an antibody developed as part of a longstanding collaboration between the two organizations.

PHILADELPHIA (July 16, 2020)—Fox Chase Cancer Center researchers have concluded that heat and moisture exchanger (HME) cassettes are more effective at preventing mucus plugs following removal of the larynx than external tracheal humidification.

PHILADELPHIA (July 16, 2020)—Fox Chase Cancer Center researchers have concluded that heat and moisture exchanger (HME) cassettes are more effective at preventing mucus plugs following removal of the larynx than external tracheal humidification.

PHILADELPHIA (July 15, 2020) – Fox Chase Cancer Center announces the hiring of Brandon Bachert, MD, who will join the department of diagnostic imaging as a full time body imager. Bachert will be an assistant professor on the academic track.

PHILADELPHIA (July 14, 2020) – J. Nicholas Bodor, MD, PhD, MPH, will join the Department of Hematology/Oncology and serve in the Thoracic Oncology Program upon completion of the Fox Chase-Temple Hematology/Oncology Fellowship Program.

PHILADELPHIA (July 13, 2020) – Genome Profiling and Fox Chase Cancer Center will collaborate to identify a novel immune system epigenetic biomarker, dubbed EpiMarker, which if successful, will be used to help predict which lung cancer patients are likely to respond to a checkpoint inhibitor therapy known as anti-PD1 antibody. These agents are a potentially valuable tool for lung cancer treatment, but it remains very difficult for doctors to predict which patients are most likely to benefit from them.